Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive...
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier Cortés speaks to ecancer about the phase 3 ASCENT-03 trial that evaluated sacituzumab govitecan (SG) versus standard chemotherapy as first-line treatment in patients with locally advanced unresectable or metastatic triple-negative breast cancer (mTNBC) who could not receive PD-(L)1 inhibitors. A total of 558 patients were randomised, and after a median follow-up of 13.2 months, SG demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a median PFS of 9.7 months compared to 6.9 months with chemotherapy. Dr Cortés says that the responses were also more durable with SG, with a median duration of response of 12.2 months versus 7.2 months. He highlights that these results support SG as a potential new standard of care for first-line mTNBC patients who are ineligible for PD-(L)1 therapy.
Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer
Tarlatamab in SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use
ASCENT - Sacituzumab govitecan in advanced triple-negative breast cancer in later lines (2+)
Tarlatamab improves survival over chemotherapy in 2L SCLC regardless of prior immunotherapy or c...
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.1 Part 2
She Asks if I Know Coldplay and This Singer Shocks The Street
Paul Newman’s Priceless Reaction to What His Wife Said Behind His Back | The Dick Cavett Show
Princess Of Boogie Woogie Delights Everyone
Golden Retriever Meets Completely Broken Rescue for the First Time
Glioblastoma Grade 4 - Terminal Brain Cancer at 34
Stop Walking 10,000 Steps/Day (do this for 10 minutes instead)
She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
SABCS 2020: Triple neg., metastasierter Brustkrebs: Neue Therapieoption mit Sacituzumab Govitecan.
Tarlatamab improves symptoms and QoL over chemotherapy in previously treated small cell lung cancer
Ivermectin to Treat Cancer? Get the FACTS
Brain Tumor: Why a Headache Isn't the First Symptom
Spine Surgeon Drowns for 30 Minutes —Comes Back With a List
It's NOT Memory - 5 Early Dementia Signs Everyone Misses
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
